Assistant Professor of Internal Medicine
Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
1st Department of Internal Medicine, University General Hospital of Ioannina
Honorary Research Fellow
Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care & Public Health, School of Public Health, Faculty of Medicine, Imperial College London, London, UK
Research Projects
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event (AZURE-Outcomes)
ClinicalTrials.gov Identifier: NCT07000357
The aim of this phase 3, randomized, placebo-controlled, event-driven study is to evaluate the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo, on reducing the risk of cardiovascular events in patients with established atherosclerotic cardiovascular disease or in individuals at high risk for a first cardiovascular event
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
ClinicalTrials.gov Identifier: NCT06077864
The objective of the study is to investigate whether survodutide (BI 456906) reduces or affects the risk of major cardiovascular events in individuals with overweight or obesity.
EPIRUS FH Reverse Cascade Screening
ClinicalTrials.gov Identifier: NCT05825612
The EPIRUS-FH registry is a model reverse screening program for familial hypercholesterolemia (FH) in children and adolescents in Northwest Greece that aims to increase public and physician awareness, to strengthen the national registry of familial hypercholesterolemia (HELLAS-FH) and to form the core for a national registry of children and adolescents with FH in Greece..
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
ClinicalTrials.gov Identifier: NCT05581303
This study will investigate the effect of olpasiran, a drug that lowers Lp(a)-lipoprotein(a) levels, in reducing morbidity and mortality in adults with coronary artery disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)
ClinicalTrials.gov Identifier: NCT05021835
This study is being conducted to see if ziltivekimab reduces the risk of cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)
ClinicalTrials.gov Identifier: NCT07037433
The primary objective of the study is to demonstrate that maridebart cafraglutide, when administered in addition to standard-of-care therapy, is superior to placebo in reducing cardiovascular morbidity and mortality in individuals with overweight or obesity.
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
ClinicalTrials.gov Identifier: NCT06292013
The aim of the study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in individuals with elevated lipoprotein(a) [Lp(a)] levels who either have established cardiovascular disease or are at increased risk of myocardial infarction or stroke.
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)
ClinicalTrials.gov Identifier: N CT05556512
This study will investigate the effect of tirzepatide in reducing morbidity and mortality in adults living with obesity and provide additional evidence on the potential clinical benefits of tirzepatide in this population.
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)
ClinicalTrials.gov Identifier: NCT05030428
This study investigates the effect of inclisiran, a cholesterol-lowering drug, on the risk of cardiovascular events in people with established cardiovascular disease.
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)
ClinicalTrials.gov Identifier: NCT03872401
This study will evaluate the effect of evolocumab, a cholesterol-lowering drug, on the risk of major cardiovascular events in adults without a previous myocardial infarction or stroke who are at high risk for a cardiovascular event.